Sanofi us­es cre­ative cam­ou­flage in physi­cian-tar­get­ed cam­paign for po­ten­tial can­cer bio­mark­er

As Sanofi stud­ies a new kind of can­cer drug, it’s prep­ping physi­cians for its po­ten­tial bio­mark­er ex­pres­sion.

Sanofi’s tusami­ta­m­ab rav­tan­sine is an an­ti­body-drug con­ju­gate (ADC) that tar­gets CEA­CAM5-ex­press­ing tu­mors and is cur­rent­ly in a Phase III study to treat ad­vanced non-small cell lung can­cer. A com­pan­ion di­ag­nos­tic test is al­so un­der de­vel­op­ment, said François-Xavier Etaix, Sanofi’s glob­al brand lead for CEA­CAM5, in an email in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER